Combination of Ibrutinib and Venetoclax in the Therapy of Chronic Lymphocytic Leukemia: A Review of the Latest Data from Clinical Studies
New Bruton’s tyrosine kinase (BTK) inhibitors caused drastic modifications in the therapy of chronic lymphocytic leukemia (CLL). Ibrutinib, the first in its class BTK inhibitor, showed high efficacy in many clinical studies. However, the treatment with BTK inhibitors as monotherapy must not be disco...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Russo |
| Publicado: |
Practical Medicine Publishing House
2023-01-01
|
| Series: | Клиническая онкогематология |
| Assuntos: | |
| Acceso en liña: | https://bloodjournal.ru/index.php/coh/article/view/5 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|